Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Figure 6: The opposing effects of insulin and AMPK activation on the target-of-rapamycin (TOR) pathway. Although studies of mammalian cells and budding yeast have provided the most detailed ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its ...